FDA starts the pri­or­i­ty re­view clock for Sym­bio­mix; Cor­ner­stone gets a green light on piv­otal stud­ies

→ The FDA ac­cept­ed Sym­bio­mix’s NDA for Solosec (sec­nida­zole oral gran­ules), an an­tibi­ot­ic de­signed to treat bac­te­r­i­al vagi­nosis, and stamped it with a pri­or­i­ty …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.